公开(公告)号：US20230172917A1

公开(公告)日：2023-06-08

申请号：US17924601

申请日：2021-06-24

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Kathleen Miho Sakamoto ,  Mark Wilkes

IPC: A61K31/4375 ,  A61K36/258 ,  A61K31/155 ,  A61P7/00

CPC classification number: A61K31/4375 ,  A61K36/258 ,  A61K31/155 ,  A61P7/00

Abstract: Methods of treating a subject for a bone marrow failure syndrome, e.g., DBA, are provided. Aspects of the methods include administering to the subject an effective amount of a Nemo-Like Kinase (NLK) inhibitor. Also provided are compositions that find use in practicing embodiment of the invention.

公开(公告)号：US20230165846A1

公开(公告)日：2023-06-01

申请号：US17799609

申请日：2021-02-09

Applicant: Gasherbrum Bio, Inc.

Inventor： Qinghua MENG ,  Xichen LIN ,  Andrew JENNINGS

IPC: A61K31/444 ,  A61K38/26 ,  A61K38/28 ,  A61K31/137 ,  A61K31/155 ,  A61K39/395 ,  A61K38/17 ,  A61K31/423 ,  A61K31/506 ,  A61K31/497 ,  C07D471/04

CPC classification number: A61K31/444 ,  A61K31/137 ,  A61K31/155 ,  A61K31/423 ,  A61K31/497 ,  A61K31/506 ,  A61K38/26 ,  A61K38/28 ,  A61K38/1709 ,  A61K39/3955 ,  C07D471/04

Abstract: Provided are GLP-1 agonists of Formula (I) or (II), including pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions, and methods of using the same.

公开(公告)号：US20230158160A1

公开(公告)日：2023-05-25

申请号：US17912424

申请日：2021-05-22

Applicant: LYRUS LIFE SCIENCES PVT. LTD. ,  NOKHA TRADING LLP

Inventor： Chandanmal Pukhraj Bothra ,  Hemanth Kumar Bothra ,  Elayaraja Natarajan ,  Chitra Ajithan Varma ,  Venkateshappa Govindappa

IPC: A61K47/58 ,  A61K47/36 ,  A61K31/155 ,  A61K31/55 ,  A61K31/445

CPC classification number: A61K47/585 ,  A61K47/36 ,  A61K31/155 ,  A61K31/55 ,  A61K31/445

Abstract: The present invention relates to extended-release suspension composition. The present invention specifically relates to extended-release suspension composition comprising active ingredient and pharmaceutically acceptable excipients, wherein said composition is in the form of powder for suspension or a ready to use suspension. The present invention specifically relates to extended-release suspension composition comprising active ingredient and pharmaceutically acceptable excipients, wherein said composition is devoid of uncoated active ingredient-ion exchange resin complex portion and polyvinyl acetate. The present invention also relates to extended-release suspension composition comprising one or more functional barrier coatings on active ingredient-ion exchange resin complex, wherein said functional barrier coatings comprises hypromellose and/or talc.

公开(公告)号：US20230149447A1

公开(公告)日：2023-05-18

申请号：US17525596

申请日：2021-11-12

Applicant: Ahmed Elkoulily, M.D.

Inventor： Ahmed Elkoulily, M.D.

IPC: A61K33/18 ,  A61K9/00 ,  A61K31/155 ,  A61K9/08 ,  A61K31/045

CPC classification number: A61K33/18 ,  A61K9/0043 ,  A61K9/0053 ,  A61K31/155 ,  A61K9/08 ,  A61K31/045

Abstract: A kit and method for providing a “second line of defense” against Corona Virus strains. The kit includes at least one nasal swab pre-moistened with an iodine solution, and at least one oral swab pre-moistened with a chlorhexidine solution. The iodine solution can be a solution of betadine 0.5-2.0%, or a povidone solution. The chlorhexidine solution is chlorhexidine 0.09% to 0.12%. The nasal swabs are preferably sealed in a resealable package. The oral swabs are preferably sealed in a separate resealable package. The kit can include alcohol swabs pre-moistened with 60%-70% Isopropyl Alcohol in a disposable sealed package. The method includes using at least one nasal swab pre-moistened with an iodine solution to apply the iodine solution to an inner surface within each of one's nostrils, and using at least one oral swab pre-moistened with chlorhexidine solution to apply the chlorhexidine solution to an inner surface of one's mouth.

公开(公告)号：US20230149314A1

公开(公告)日：2023-05-18

申请号：US17915826

申请日：2021-03-12

Applicant: HANMI PHARM. CO., LTD.

Inventor： Jin Wook TAK ,  Bo Sik KIM ,  Taek Kwan KWON ,  Ho Taek IM ,  Yong II KIM

IPC: A61K9/24 ,  A61K9/20 ,  A61K31/7034 ,  A61K31/4985 ,  A61K31/155

CPC classification number: A61K9/209 ,  A61K9/2009 ,  A61K31/7034 ,  A61K31/4985 ,  A61K31/155 ,  A61K9/2077 ,  A61K9/2095

Abstract: According to an aspect, provided are a composite tablet and a method of preparing the composite tablet, wherein the composite tablet may include a first layer including dry granules that include sitagliptin or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and dapagliflozin or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a second layer including wet granules that include metformin or a pharmaceutically acceptable salt thereof and colloidal silicon dioxide.

公开(公告)号：US20230133954A1

公开(公告)日：2023-05-04

申请号：US17516262

申请日：2021-11-01

Applicant: Medtronic, Inc.

Inventor： Valentino J. Tramontano ,  Kevin P. Trainor

IPC: A61K9/12 ,  A61K33/38 ,  A61K31/155

Abstract: In some examples, an antimicrobial article including a foam member. The foam member includes a polymer matrix and at least one antimicrobial agent encapsulated in a water permeable polymer. The polymer matrix of the foam member defines a plurality of void volumes. In some examples, the antimicrobial article including the foam member may be used in a wound dressing application.

公开(公告)号：US20230132922A1

公开(公告)日：2023-05-04

申请号：US17911948

申请日：2021-07-20

Applicant: Chandanmal Pukhraj BOTHRA ,  Hemanth Kumar BOTHRA ,  Elayaraja NATARAJAN ,  Siva Ram MUNNANGI ,  Manmath Nana THALKARI ,  Manivel THANGAPRAGASAM ,  LYRUS LIFE SCIENCES PVT. LTD. ,  NOKHA TRADING LLP

Inventor： Chandanmal Pukhraj Bothra ,  Hemanth Kumar Bothra ,  Elayaraja Natarajan ,  Siva Ram Munnangi ,  Manmath Nana Thalkari ,  Manivel Thangapragasam

IPC: A61K9/50 ,  A61K9/48 ,  A61K31/167 ,  A61K31/616 ,  A61K31/192 ,  A61K31/155 ,  A61K31/485 ,  A61K31/495 ,  A61K31/593 ,  A61K31/451 ,  A61K9/00 ,  A61K47/12 ,  A61K47/26 ,  A61K47/18 ,  A61K47/02

Abstract: The present invention relates to Rapid melt granules prepared by encapsulation and complexation processes. The present invention specifically relates to Rapid melt granules prepared by novel process of particulate coating comprising the steps of encapsulation of active ingredient with encapsulation polymer and/or pore former, drying, blending, optionally polymer coating, drying before blending and filling into sachets or compressing into tablets. The present invention more specifically relates to Rapid melt granules prepared by novel process of complexation comprising the steps of complexation of active ingredient with sulfonated polymers of ion exchange resin, drying, blending, optionally polymer coating, drying before blending and filling into sachets or compressing into tablets.

公开(公告)号：US20230115416A1

公开(公告)日：2023-04-13

申请号：US17962381

申请日：2022-10-07

Applicant: Todd EWING

Inventor： Todd EWING

IPC: A61K31/198 ,  A61K31/205 ,  A61K31/4745 ,  A61K31/132 ,  A61K31/155 ,  A61K33/06 ,  A61K33/00 ,  A61K31/566 ,  A61K31/573 ,  A61K31/385 ,  A61K31/455 ,  A61K31/19 ,  A61K33/22 ,  A61K35/741 ,  A61K35/76 ,  A61P3/02 ,  A61K9/00

Abstract: Provided are methods and compositions for promoting cellular metabolism and cellular repair in a tissue of a subject in need thereof. The composition includes at least one N-methyl-D-aspartate receptor (NMDAR) modulator to modulate metabolic activity in cells and at least one nuclear factor erythroid 2-related factor 2 (NRF2) modulator to modulate repair activity in cells. Optionally, the composition also includes at least one inactive component and at last one microbial modulator. The composition synergistically modulates a positive-feedback signal-amplification cycle comprising NMDAR and NRF2 in cells, which, in turn, promotes cellular metabolic fitness (CMF) in a tissue of a subject in need thereof.

公开(公告)号：US11617729B2

公开(公告)日：2023-04-04

申请号：US16925260

申请日：2020-07-09

Applicant: Yanping Kong ,  Jinhong Liu

Inventor： Yanping Kong ,  Jinhong Liu

IPC: A61K31/155 ,  A61P35/00

Abstract: The uses of guanidine hydrochloride as a drug for treating cancers/tumors. Guanidine hydrochloride can destroy the formation of hydrogen bonds by polar molecules on the surface of cancer cells and the macromolecules taken up, thereby demonstrating that guanidine hydrochloride can inhibit the uptake by cancer cells. The present invention provides new uses of guanidine hydrochloride in the treatment of subjects suffering from cancers/tumors and prevention of recurrence after cancer operation. The dose of guanidine hydrochloride administration is 10-35 mg/kg a day. The hydrochloride dose of the guanidine has a significant inhibitory effect on the uptake of DNA by cancer cells, which in turn can effectively inhibit the proliferation of cancer cells; besides, the inhibition rate of liver cancer tumors 9 days after the injection of guanidine hydrochloride drugs can reach 42%, and the inhibition rate of lung cancer tumors 7 days after the injection of guanidine hydrochloride drugs reach 56.8%.

公开(公告)号：US11612613B2

公开(公告)日：2023-03-28

申请号：US16637853

申请日：2018-08-08

Applicant: Robert Petcavich

Inventor： Robert Petcavich

IPC: A61K31/7016 ,  A61K9/00 ,  A61K31/436 ,  A61K31/155

Abstract: A pharmaceutically acceptable composition comprising trehalose and a pharmaceutically acceptable excipient and methods of delivering autophagy stimulating trehalose to a patient in need thereof.